Senior Associate Scientist, Investigative Sciences

This role is considered On-Site.

Overview

The Investigative Sciences group within Early Development is seeking a Senior Associate Scientist to join our team. The successful candidate will support a variety of investigative, cell and molecular mechanism-based research efforts to evaluate target pharmacology, nonclinical safety, and advance Alnylam’s RNAi platform across liver, CNS, and other tissues.

Key Responsibilities

• Contribute to study design and execution of in vivo experiments to characterize preclinical pharmacology and safety and address novel platform questions across multiple tissues/therapeutic areas
• Perform ex vivo assays, including but not limited to qPCR and ELISA, to support in vivo studies
• Analyze, collate and interpret data for reports and presentations to cross-functional groups
• Collaboratively interact with other scientists to accomplish cross-disciplinary objectives
• Maintain excellent experimental records in an Electronic Lab Notebook

Qualifications

• Minimum B.S. degree in a life sciences-related discipline such as Physiology, Cell/Molecular Biology, or related field.
• 2+ years of post-degree experience executing in vivo and ex vivo experiments in an industrial or academic setting
• Experience handling rodents (mouse, rat) and performing dosing (IP, SC) and tissue harvesting/necropsy
• Proficiency performing molecular biology techniques (including nucleic acid purification and RT-qPCR) and biochemistry techniques (ELISA, Western blot)
• Experience with methods and models for metabolic assessment in mouse is a plus
• Experience with fluorescence and/or bioluminescence imaging is a plus
• Ability to design experiments with an understanding of underlying scientific principles and independently analyze results
• Must be a team player with good interpersonal skills, open to new tasks and challenges

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.